The potential for proarrhythmic events with ibutilide increases with the coadministration of other drugs that prolong the QT interval. Iloperidone: Major Avoid coadministration of azithromycin with iloperidone due to the increased risk of QT prolongation. Iloperidone has been associated with QT prolongation. Imipramine: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation.
Indacaterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Indacaterol; Glycopyrrolate: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Inotuzumab Ozogamicin: Major Avoid coadministration of inotuzumab ozogamicin with azithromycin due to the potential for additive QT interval prolongation and risk of torsade de pointes TdP.
If coadministration is unavoidable, obtain an ECG and serum electrolytes prior to the start of treatment, after treatment initiation, and periodically during treatment. Avoid any non-essential QT prolonging drugs and correct electrolyte imbalances. Inotuzumab has been associated with QT interval prolongation. QT prolongation and TdP have been spontaneously reported during azithromycin postmarketing surveillance.
Ipratropium; Albuterol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Isoflurane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation.
Itraconazole: Major Avoid coadministration of azithromycin with itraconazole due to the increased risk of QT prolongation. Itraconazole has been associated with prolongation of the QT interval. Ivosidenib: Major Avoid coadministration of azithromycin with ivosidenib due to an increased risk of QT prolongation. An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs.
Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. Ketoconazole: Major Avoid coadministration of azithromycin with ketoconazole due to the increased risk of QT prolongation. Ketoconazole has been associated with prolongation of the QT interval. Lapatinib: Major Avoid coadministration of azithromycin with lapatinib due to the increased risk of QT prolongation.
Lapatinib has been associated with concentration-dependent QT prolongation; ventricular arrhythmias and TdP have been reported in postmarketing experience with lapatinib. Lefamulin: Major Avoid coadministration of azithromycin with lefamulin as concurrent use may increase the risk of QT prolongation.
Lefamulin has a concentration dependent QTc prolongation effect. The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between lefamulin and other drugs that effect cardiac conduction is unknown. Lenvatinib: Major Avoid coadministration of azithromycin with lenvatinib due to the increased risk of QT prolongation. Prolongation of the QT interval has been reported with lenvatinib therapy. Leuprolide: Major Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT prolongation.
Leuprolide; Norethindrone: Major Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT prolongation. Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Levalbuterol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Levofloxacin: Major Avoid coadministration of azithromycin with levofloxacin due to the increased risk of QT prolongation.
Levofloxacin has been associated with a risk of QT prolongation and TdP. Although extremely rare, TdP has been reported during postmarketing surveillance of levofloxacin. Levonorgestrel: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Levonorgestrel; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Levonorgestrel; Ethinyl Estradiol; Ferrous Bisglycinate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Lithium: Major Avoid coadministration of azithromycin with lithium due to the increased risk of QT prolongation. Lithium has also been associated with QT prolongation. Lofexidine: Major Avoid coadministration of azithromycin with lofexidine due to the increased risk of QT prolongation. Lofexidine prolongs the QT interval. Long-acting beta-agonists: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Loperamide: Major Avoid coadministration of azithromycin with loperamide due to the increased risk of QT prolongation.
At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest.
Loperamide; Simethicone: Major Avoid coadministration of azithromycin with loperamide due to the increased risk of QT prolongation. Lopinavir; Ritonavir: Major Avoid coadministration of azithromycin with lopinavir; ritonavir due to the increased risk of QT prolongation.
Lopinavir; ritonavir is associated with QT prolongation. Macimorelin: Major Avoid coadministration of azithromycin with macimorelin due to the increased risk of QT prolongation and torsade de pointes-type ventricular tachycardia. Sufficient washout time of drugs that are known to prolong the QT interval prior to administration of macimorelin is recommended. Treatment with macimorelin has been associated with an increase in the corrected QT QTc interval.
Maprotiline: Major Avoid coadministration of azithromycin with maprotiline due to the increased risk of QT prolongation. Maprotiline has been reported to prolong the QT interval, particularly in overdose or with higher-dose prescription therapy elevated serum concentrations. Cases of long QT syndrome and TdP tachycardia have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and in the absence of other known risk factors for QT prolongation.
Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. Mefloquine: Major Avoid coadministration of azithromycin with mefloquine due to the increased risk of QT prolongation. There is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc interval. Mefloquine alone has not been reported to cause QT prolongation. Meperidine; Promethazine: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation.
Mestranol; Norethindrone: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Metaproterenol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Methadone: Major Avoid coadministration of azithromycin with methadone due to the increased risk of QT prolongation. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction.
Midostaurin: Major Avoid coadministration of azithromycin with midostaurin due to the increased risk of QT prolongation. QT prolongation was reported in patients who received midostaurin in clinical trials.
Mifepristone: Major Avoid coadministration of azithromycin with mifepristone due to the increased risk of QT prolongation. Mifepristone has been associated with dose-dependent prolongation of the QT interval. Mirtazapine: Major Avoid coadministration of azithromycin with mirtazapine due to the increased risk of QT prolongation.
Mirtazapine has been associated with dose-dependent prolongation of the QT interval. TdP has been reported postmarketing, primarily in overdose or in patients with other risk factors for QT prolongation. Moxifloxacin: Major Avoid coadministration of azithromycin with moxifloxacin due to the increased risk of QT prolongation. Quinolones have been associated with a risk of QT prolongation. Although extremely rare, TdP has been reported during postmarketing surveillance of moxifloxacin.
These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory. Nelfinavir: Moderate Coadministration of nelfinavir and azithromycin results in increased azithromycin concentrations. Dosage adjustments are not necessary, although patients should be monitored for azithromycin related adverse effects such as increased hepatic enzymes and hearing impairment.
Nilotinib: Major Avoid coadministration of azithromycin with nilotinib due to the increased risk of QT prolongation. Sudden death and QT prolongation have been reported in patients who received nilotinib therapy. Norethindrone Acetate; Ethinyl Estradiol; Ferrous fumarate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Norethindrone: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Norethindrone; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Norethindrone; Ethinyl Estradiol; Ferrous fumarate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Norgestimate; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Norgestrel: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Nortriptyline: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Octreotide: Major Avoid coadministration of azithromycin with octreotide due to the increased risk of QT prolongation.
Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy. Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval. Ofloxacin: Major Avoid coadministration of azithromycin with ofloxacin due to the increased risk of QT prolongation. Quinolones have been associated with a risk of QT prolongation and TdP.
Although extremely rare, TdP has been reported during postmarketing surveillance of ofloxacin. Olanzapine: Major Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation.
Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. Olanzapine; Fluoxetine: Major Avoid coadministration of azithromycin with fluoxetine due to the increased risk of QT prolongation. Major Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation.
Olanzapine; Samidorphan: Major Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation. Olodaterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Ondansetron: Major Avoid coadministration of azithromycin with ondansetron due to the increased risk of QT prolongation. Ondansetron has been associated with a dose-related increase in the QT interval and postmarketing reports of TdP.
Oral Contraceptives: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Osilodrostat: Major Avoid coadministration of azithromycin with osilodrostat due to the increased risk of QT prolongation. Osilodrostat is associated with dose-dependent QT prolongation. Osimertinib: Major Avoid coadministration of azithromycin with osimertinib if possible due to the risk of QT prolongation and torsade de pointes TdP. An interruption of osimertinib therapy with dose reduction or discontinuation may be necessary if QT prolongation occurs.
Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib. Oxaliplatin: Major Avoid coadministration of azithromycin with oxaliplatin due to the increased risk of QT prolongation. QT prolongation and ventricular arrhythmias including fatal TdP have been reported with oxaliplatin use in postmarketing experience. Ozanimod: Major Avoid coadministration of azithromycin with ozanimod due to the increased risk of QT prolongation.
Ozanimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ozanimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia. Paliperidone: Major Avoid coadministration of azithromycin with paliperidone due to the increased risk of QT prolongation. Paliperidone has been associated with QT prolongation; torsade de pointes and ventricular fibrillation have been reported in the setting of overdose.
Panobinostat: Major Avoid coadministration of azithromycin with panobinostat due to the increased risk of QT prolongation. QT prolongation has been reported with panobinostat. Pasireotide: Major Avoid coadministration of azithromycin with pasireotide due to the increased risk of QT prolongation. QT prolongation has also occurred with pasireotide at therapeutic and supra-therapeutic doses. Pazopanib: Major Avoid coadministration of azithromycin with pazopanib due to the increased risk of QT prolongation.
Pazopanib has been reported to prolong the QT interval. Pentamidine: Major Avoid coadministration of azithromycin with pentamidine due to the increased risk of QT prolongation. Systemic pentamidine has been associated with QT prolongation. Perphenazine: Major Avoid coadministration of azithromycin with perphenazine due to the increased risk of QT prolongation.
Perphenazine is associated with a possible risk for QT prolongation. Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation.
Perphenazine; Amitriptyline: Major Avoid coadministration of azithromycin with perphenazine due to the increased risk of QT prolongation. Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Phenytoin: Minor Until more data are available, the manufacturer of azithromycin recommends caution and careful monitoring of patients who receive azithromycin with phenytoin.
Azithromycin was not implicated in clinical trials with drug interactions with phenytoin. However, specific drug interaction studies have not been performed with the combination of azithromycin and phenytoin. Pimavanserin: Major Avoid coadministration of azithromycin with pimavanserin due to the increased risk of QT prolongation. Pimavanserin prolongs the QT interval. Pimozide: Contraindicated Pimozide is associated with a well-established risk of QT prolongation and torsade de pointes TdP.
Because of the potential for TdP, use of macrolide antibiotics with pimozide is contraindicated. Pirbuterol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Pitolisant: Major Avoid coadministration of azithromycin with pitolisant due to the increased risk of QT prolongation. Pitolisant prolongs the QT interval. Ponesimod: Major Avoid coadministration of azithromycin with ponesimod due to the increased risk of QT prolongation.
Ponesimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ponesimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia Posaconazole: Major Avoid coadministration of azithromycin with posaconazole due to the increased risk of QT prolongation.
Posaconazole has been associated with prolongation of the QT interval as well as rare cases of TdP. Pravastatin: Moderate Azithromycin has the potential to increase pravastatin exposure when used concomitantly.
Primaquine: Major Avoid coadministration of azithromycin with primaquine due to the increased risk of QT prolongation. Primaquine has the potential for QT interval prolongation.
Probenecid; Colchicine: Moderate Caution is warranted with the concomitant use of colchicine and azithromycin as increased colchicine concentrations may occur. Procainamide: Major Avoid coadministration of azithromycin with procainamide due to the increased risk of QT prolongation. Procainamide is associated with a well-established risk of QT prolongation and TdP.
Prochlorperazine: Major Avoid coadministration of azithromycin with prochlorperazine due to the increased risk of QT prolongation. Prochlorperazine is associated with a possible risk for QT prolongation. Theoretically, prochlorperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation.
Promethazine: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. Promethazine; Dextromethorphan: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. Promethazine; Phenylephrine: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation.
Propafenone: Major Avoid coadministration of azithromycin with propafenone due to the increased risk of QT prolongation. Protriptyline: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Quetiapine: Major Avoid coadministration of azithromycin with quetiapine due to the increased risk of QT prolongation.
Limited data, including some case reports, suggest that quetiapine may be associated with a significant prolongation of the QTc interval in rare instances. Quinidine: Major Avoid coadministration of azithromycin with quinidine due to the increased risk of QT prolongation.
Quinine: Major Avoid coadministration of azithromycin with quinine due to the increased risk of QT prolongation. Quinine has been associated with QT prolongation and rare cases of TdP.
Ranolazine: Major Avoid coadministration of azithromycin with ranolazine due to the increased risk of QT prolongation. Ranolazine is associated with dose- and plasma concentration-related increases in the QTc interval.
Although there are no studies examining the effects of ranolazine in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation. Relugolix: Major Avoid coadministration of azithromycin with relugolix due to the increased risk of QT prolongation.
Relugolix; Estradiol; Norethindrone acetate: Major Avoid coadministration of azithromycin with relugolix due to the increased risk of QT prolongation. Ribociclib: Major Avoid coadministration of azithromycin with ribociclib due to the increased risk of QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner.
The ribociclib ECG changes occurred within the first four weeks of treatment and were reversible with dose interruption. Ribociclib; Letrozole: Major Avoid coadministration of azithromycin with ribociclib due to the increased risk of QT prolongation. Rilpivirine: Major Avoid coadministration of azithromycin with rilpivirine due to the increased risk of QT prolongation. Risperidone: Major Avoid coadministration of azithromycin with risperidone due to the increased risk of QT prolongation.
Romidepsin: Major Avoid coadministration of azithromycin with romidepsin due to the increased risk of QT prolongation. Romidepsin has been reported to prolong the QT interval. Salmeterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.
Saquinavir: Major Avoid coadministration of azithromycin with saquinavir boosted with ritonavir due to the increased risk of QT prolongation. Saquinavir boosted with ritonavir increases the QT interval in a dose-dependent fashion, which may increase the risk for serious arrhythmias such as TdP. Segesterone Acetate; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Selpercatinib: Major Avoid coadministration of azithromycin and selpercatinib due to the risk of additive QT prolongation.
Monitor ECG and electrolytes and avoid other non-essential QT prolonging drugs if use together is required. Concentration-dependent QT prolongation has been observed with selpercatinib therapy. Sertraline: Major Avoid coadministration of azithromycin with sertraline due to the increased risk of QT prolongation.
Sertraline's FDA-approved labeling recommends avoiding concomitant use with drugs known to prolong the QTc interval; however, the risk of sertraline-induced QT prolongation is generally considered to be low in clinical practice. Its effect on QTc interval is minimal typically less than 5 msec , and the drug has been used safely in patients with cardiac disease e.
Sevoflurane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. Short-acting beta-agonists: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Siponimod: Major Avoid coadministration of azithromycin with siponimod due to the increased risk of QT prolongation.
Siponimod therapy prolonged the QT interval at recommended doses in a clinical study. Sodium picosulfate; Magnesium oxide; Anhydrous citric acid: Major Prior or concomitant use of antibiotics with sodium picosulfate; magnesium oxide; anhydrous citric acid may reduce efficacy of the bowel preparation as conversion of sodium picosulfate to its active metabolite bis- p-hydroxy-phenyl -pyridylmethane BHPM is mediated by colonic bacteria.
If possible, avoid coadministration. Certain antibiotics i. Therefore, these antibiotics should be taken at least 2 hours before and not less than 6 hours after the administration of sodium picosulfate; magnesium oxide; anhydrous citric acid solution.
Solifenacin: Major Avoid coadministration of azithromycin with solifenacin due to the increased risk of QT prolongation. Solifenacin has been associated with dose-dependent prolongation of the QT interval. TdP has been reported with postmarketing use, although causality was not determined. Sorafenib: Major Avoid coadministration of azithromycin with sorafenib due to the increased risk of QT prolongation.
An interruption or discontinuation of sorafenib therapy may be necessary if QT prolongation occurs. Sorafenib is also associated with QTc prolongation. Sotalol: Major Avoid coadministration of azithromycin with sotalol due to the increased risk of QT prolongation. Sotalol administration is associated with QT prolongation and TdP. Proarrhythmic events should be anticipated after initiation of therapy and after each upward dosage adjustment. Sunitinib: Major Avoid coadministration of azithromycin with sunitinib due to the increased risk of QT prolongation.
Sunitinib can cause dose-dependent QT prolongation, which may increase the risk for ventricular arrhythmias, including TdP. Tacrolimus: Major Avoid coadministration of azithromycin with tacrolimus due to the increased risk of QT prolongation.
Tacrolimus may prolong the QT interval and cause TdP. Talazoparib: Moderate Monitor for an increase in talazoparib-related adverse reactions if coadministration with azithromycin is necessary. Tamoxifen: Major Avoid coadministration of azithromycin with tamoxifen due to the increased risk of QT prolongation.
Tamoxifen has been reported to prolong the QT interval, usually in overdose or when used in high doses. Rare case reports of QT prolongation have also been described when tamoxifen is used at lower doses. Telavancin: Major Avoid coadministration of azithromycin with telavancin due to the increased risk of QT prolongation. Telavancin has been associated with QT prolongation.
Telithromycin: Major Avoid coadministration of azithromycin with telithromycin due to the increased risk of QT prolongation. Telithromycin is also associated with QT prolongation and TdP. Terbutaline: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation.
Tetrabenazine: Major Avoid coadministration of azithromycin with tetrabenazine due to the increased risk of QT prolongation. Tetrabenazine causes a small increase in the corrected QT interval QTc. Thioridazine: Contraindicated Coadministration of thioridazine and azithromycin is contraindicated due to an increased risk of QT prolongation.
Thioridazine is associated with a well-established risk of QT prolongation and TdP. Tiotropium; Olodaterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.
Tolterodine: Major Avoid coadministration of azithromycin with tolterodine due to the increased risk of QT prolongation. Tolterodine has been associated with dose-dependent prolongation of the QT interval, especially in poor CYP2D6 metabolizers. Toremifene: Major Avoid coadministration of azithromycin with toremifene if possible due to the risk of additive QT prolongation. Toremifene has been shown to prolong the QTc interval in a dose- and concentration-related manner.
Trazodone: Major Avoid coadministration of azithromycin with trazodone due to the increased risk of QT prolongation. In addition, there are postmarketing reports of TdP.
Triclabendazole: Major Avoid coadministration of azithromycin with triclabendazole due to the increased risk of QT prolongation. Transient prolongation of the mean QTc interval was noted on the ECG recordings in dogs administered triclabendazole. Tricyclic antidepressants: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Trifluoperazine: Major Avoid coadministration of azithromycin with trifluoperazine due to the increased risk of QT prolongation.
Trifluoperazine is associated with a possible risk for QT prolongation. Theoretically, trifluoperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation.
Trimipramine: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation.
However, because drugs affect each person differently, we cannot guarantee that this list includes all possible dosages. Always speak with your doctor or pharmacist about dosages that are right for you. Azithromycin is typically used for short-term treatment. For azithromycin to work well, a certain amount needs to be in your body at all times.
If you take too much: You could have dangerous levels of the drug in your body. This may cause liver damage or an irregular heart rhythm. If your symptoms are severe, call or go to the nearest emergency room right away.
What to do if you miss a dose: Take your dose as soon as you remember. But if you remember just a few hours before your next scheduled dose, take only one dose. Never try to catch up by taking two doses at once. This could result in dangerous side effects. If you take too much azithromycin, you could have dangerous levels of the drug in your body.
This may cause liver damage and irregular heart rhythm. A prescription for this medication is refillable. You should not need a new prescription for this medication to be refilled. Your doctor will write the number of refills authorized on your prescription.
A class of drugs is a group of medications that work in a similar way. These drugs are often used to treat similar conditions. Azithromycin belongs to a drug class called macrolide antibiotics. Antibiotics are drugs used to treat infections caused by bacteria. Each antibiotic only works against infections caused by certain types of bacteria, so there are many classes and types of antibiotics.
Macrolide antibiotics are typically used to treat infections such as strep throat , syphilis , Lyme disease , and respiratory infections. The other macrolide antibiotics available in the United States are clarithromycin and erythromycin.
There are other drugs available to treat your condition. Some may be better suited for you than others. Talk to your doctor about other drug options that may work for you. A: One difference is that while both of these drugs work by killing bacteria, they do it in different ways. Azithromycin belongs to the class of drugs called macrolide antibiotics, as described in this article. Amoxicillin belongs to a class called beta-lactam antibiotics.
This is a large class that includes drugs such as penicillin. Azithromycin and amoxicillin can be used to treat several of the same conditions. These include bronchitis , sinusitis , strep throat, pneumonia, ear infections, skin infections, and lower respiratory infections. However, they have differences. Azithromycin can also be used to treat gonorrhea, mycobacterium avium complex, and pelvic inflammatory disease. And amoxicillin can also be used to treat urinary tract infections and H.
The greatest difference to you may be how often you need to take them. Azithromycin may be taken once per day for 1 to 5 days, depending on the condition being treated. On the other hand, amoxicillin is often taken two or three times per day for 10 to 14 days. Answers represent the opinions of our medical experts. All content is strictly informational and should not be considered medical advice.
Try to take your medicine at the same time each day. The usual dose is mg a day for 3 to 10 days depending on the infection being treated. For some infections, you'll be given a one-off higher dose of 1g or 2g. The dose may be lower for children or if you have liver or kidney problems. Azithromycin is sometimes prescribed long term to prevent chest infections if you keep getting them. In this case, it's usually taken 3 times a week, often on a Monday, Wednesday and Friday.
Carry on taking this medicine until the course is completed, even if you feel better. If you stop your treatment early, your infection could come back. If your doctor has prescribed azithromycin capsules, you should take them at least 1 hour before food or 2 hours after eating. Azithromycin liquid is available for children and people who find it difficult to swallow tablets.
If you or your child are taking azithromycin as a liquid, it'll usually be made up for you by your pharmacist. The medicine will come with a syringe or spoon to help you measure the right amount. If you don't have one, ask your pharmacist for one. Do not use a kitchen teaspoon as it will not give the right amount. The liquid can have a bitter aftertaste, so it can be a good idea to offer children a drink of fruit juice afterwards.
If you forget to take a dose, take it as soon as you remember, unless it's nearly time for your next one. In this case, just leave out the missed dose and take your next dose as normal. Never take 2 doses at the same time. Never take an extra dose to make up for a forgotten one. If you often forget doses, it may help to set an alarm to remind you.
You could also ask your pharmacist for other ways to remember your medicine. Taking an extra dose of azithromycin by accident is unlikely to harm you or your child. It may, however, increase the chance of temporary side effects, such as feeling or being sick or diarrhoea. Talk to your pharmacist or doctor if you're worried, or if you or your child accidentally take more than 1 extra dose. Like all medicines, azithromycin can cause side effects, although not everyone gets them.
These common side effects of azithromycin happen in more than 1 in people. Keep taking the medicine, but talk to your doctor or pharmacist if these side effects bother you or don't go away:. In rare cases it's possible to have a serious allergic reaction anaphylaxis to azithromycin.
These aren't all the side effects of azithromycin. For a full list, see the leaflet inside your medicine packet. Azithromycin isn't normally recommended during pregnancy or while breastfeeding. But your doctor may prescribe it if the benefits of taking azithromycin are greater than the risks. Tell your doctor if you're taking these medicines before you start azithromycin:. You should also let your doctor know if you're taking any medicines for an irregular heartbeat arrhythmia , such as amiodarone or sotalol.
Azithromycin can sometimes affect your heartbeat, so it's best not to take it with other medicines that have the same side effect. For this reason, it's important that you tell your doctor if you're taking medicines that can affect your heartbeat as a side effect. Check the leaflets that come with your medicines and talk to a pharmacist or your doctor if you have any worries.
There are no known problems with taking herbal remedies or supplements alongside azithromycin. Tell your doctor or pharmacist if you're taking any other medicines, including herbal medicines, vitamins or supplements. Azithromycin is from a group of medicines called macrolide antibiotics. Macrolide antibiotics work by killing the bacteria that cause the infection. There are other macrolide antibiotics that work in the same way as azithromycin. They include erythromycin and clarithromycin.
It's usual to take azithromycin once a day.
0コメント